{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:34:16Z","timestamp":1792096456525,"version":"4.4.0"},"reference-count":124,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Thrombotic microangiopathy (TMA) is a pathological condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and ischemic organ dysfunction due to microvascular endothelial damage and thrombosis. It affects \u223c0.8%\u201314% of kidney transplant recipients, and may manifest as either a recurrent or de novo disease. While systemic manifestations are commonly anticipated, kidney-limited TMA can also occur and is not rare. Histopathologic examination of allograft biopsies shows morphologic features indicating endothelial injury, and repeated episodes of TMA may result in coexisting acute and chronic lesions within the same patient. In transplant recipients, multiple triggers contribute to endothelial damage, including ischemia-reperfusion injury, antibody-mediated rejection, immunosuppressive agents (calcineurin and mTOR inhibitors), and infections. The risk is particularly important in individuals with genetic variants that dysregulate the alternative complement pathway. In de novo TMA, environmental triggers and transplant-related stressors play a central role, whereas genetic predisposition is the primary factor in recurrent cases. Notably, these mechanisms often overlap and may act synergistically. Recurrent atypical hemolytic uremic syndrome can successfully be managed with terminal complement inhibitors, and prophylactic use of eculizumab in the peri-transplant period has significantly reduced recurrence rates. Management of de novo TMA begins with the identification and removal of precipitating factors. In cases where no clear trigger is found, or when the disease proves refractory to conventional therapy, terminal complement inhibition may be an effective therapeutic option.<\/jats:p>\n                  <jats:p>The prognosis of recurrent TMA has improved substantially with the advent of complement targeting therapies but research is still needed to optimize management strategies.<\/jats:p>","DOI":"10.1093\/ckj\/sfag018","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:49:36Z","timestamp":1769258976000},"source":"Crossref","is-referenced-by-count":6,"title":["Thrombotic microangiopathy after kidney transplantation: diagnosis and management strategies"],"prefix":"10.1093","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0362-8154","authenticated-orcid":false,"given":"Safak","family":"Mirioglu","sequence":"first","affiliation":[{"name":"Istanbul Faculty of Medicine, Istanbul University Division of Nephrology, Department of Internal Medicine, , Istanbul ,","place":["Turkey"]},{"name":"Aziz Sancar Institute of Experimental Medicine, Istanbul University Department of Immunology, , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6925-1989","authenticated-orcid":false,"given":"Johann","family":"Morelle","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospitals Namur (CHU UCL Namur) , Namur ,","place":["Belgium"]},{"name":"de Duve Institute , UCLouvain, Brussels ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-9061","authenticated-orcid":false,"given":"Orhan","family":"Efe","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Massachusetts General Hospital , Mass General Brigham, Boston, MA ,","place":["USA"]},{"name":"Harvard Medical School , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozge","family":"Hurdogan","sequence":"additional","affiliation":[{"name":"Istanbul Faculty of Medicine, Istanbul University Department of Pathology, , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Burak","family":"Dirim","sequence":"additional","affiliation":[{"name":"Istanbul Faculty of Medicine, Istanbul University Division of Nephrology, Department of Internal Medicine, , Istanbul ,","place":["Turkey"]},{"name":"Aziz Sancar Institute of Experimental Medicine, Istanbul University Department of Genetics, , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7529-3010","authenticated-orcid":false,"given":"Gizem","family":"Kumru","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Ankara University Faculty of Medicine , Ankara ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9423-4849","authenticated-orcid":false,"given":"Krista L","family":"Lentine","sequence":"additional","affiliation":[{"name":"SSM Health Saint Louis University Hospital Transplant Center, Saint Louis University , St. Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3816-8047","authenticated-orcid":false,"given":"Yasar","family":"Caliskan","sequence":"additional","affiliation":[{"name":"SSM Health Saint Louis University Hospital Transplant Center, Saint Louis University , St. Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"2026031808523615900_bib1","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1097\/TP.0000000000004585","article-title":"TMA in kidney transplantation","volume":"107","author":"Imanifard","year":"2023","journal-title":"Transplantation"},{"key":"2026031808523615900_bib2","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1681\/ASN.0000000645","article-title":"Post-transplant thrombotic microangiopathy","volume":"36","author":"Java","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026031808523615900_bib3","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1093\/ndt\/gfaf091","article-title":"Complement activation in secondary thrombotic microangiopathies","volume":"40","author":"Morelle","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026031808523615900_bib4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","article-title":"An expert discussion on the atypical hemolytic uremic syndrome nomenclature-identifying a road map to precision: a report of a National Kidney Foundation Working Group","volume":"106","author":"Nester","year":"2024","journal-title":"Kidney Int"},{"key":"2026031808523615900_bib5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","article-title":"Renal thrombotic microangiopathy: a review","volume":"81","author":"Genest","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"2026031808523615900_bib6","doi-asserted-by":"publisher","first-page":"642864","DOI":"10.3389\/fmed.2021.642864","article-title":"Thrombotic microangiopathy after kidney transplantation: an underdiagnosed and potentially reversible entity","volume":"8","author":"\u00c1vila","year":"2021","journal-title":"Front Med"},{"key":"2026031808523615900_bib7","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.ajkd.2003.07.008","article-title":"Thrombotic microangiopathy after renal transplantation in the United States","volume":"42","author":"Reynolds","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2026031808523615900_bib8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.trre.2017.10.001","article-title":"De novo thrombotic microangiopathy after kidney transplantation","volume":"32","author":"Garg","year":"2018","journal-title":"Transplant Rev"},{"key":"2026031808523615900_bib9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in secondary thrombotic microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026031808523615900_bib10","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.kint.2024.09.012","article-title":"Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum","volume":"106","author":"Kavanagh","year":"2024","journal-title":"Kidney Int"},{"key":"2026031808523615900_bib11","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/j.1600-6143.2010.03178.x","article-title":"De novo thrombotic microangiopathy in renal allograft biopsies-role of antibody-mediated rejection","volume":"10","author":"Satoskar","year":"2010","journal-title":"Am J Transplant"},{"key":"2026031808523615900_bib12","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/ajkd.2003.50058","article-title":"De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy","volume":"41","author":"Schwimmer","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2026031808523615900_bib13","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.ajt.2024.01.029","article-title":"De novo thrombotic microangiopathy after kidney transplantation in adults: interplay between complement genetics and multiple endothelial injury","volume":"24","author":"Dessaix","year":"2024","journal-title":"Am J Transplant"},{"key":"2026031808523615900_bib14","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"2026031808523615900_bib15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/00005792-200003000-00003","article-title":"Hemolytic uremic syndrome. Recurrence after renal transplantation.","volume":"79","author":"Lahlou","year":"2000","journal-title":"Medicine"},{"key":"2026031808523615900_bib16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2215\/CJN.00050505","article-title":"Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background","volume":"1","author":"Bresin","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026031808523615900_bib17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1053\/j.ackd.2021.11.006","article-title":"Thrombotic microangiopathy syndromes-common ground and distinct frontiers","volume":"29","author":"Hanna","year":"2022","journal-title":"Adv Chronic Kidney Dis"},{"key":"2026031808523615900_bib18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: improving global outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"2026031808523615900_bib19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11113124","article-title":"Vascular occlusion in kidney biopsy is characteristic of clinically manifesting thrombotic microangiopathy","volume":"11","author":"Kovala","year":"2022","journal-title":"J Clin Med"},{"key":"2026031808523615900_bib20","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"key":"2026031808523615900_bib21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.23876\/j.krcp.20.003","article-title":"Diagnosis of renal transplant rejection: Banff classification and beyond","volume":"39","author":"Jeong","year":"2020","journal-title":"Kidney Res Clin Pract"},{"key":"2026031808523615900_bib22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2215\/CJN.05870710","article-title":"Thrombotic microangiopathy and peritubular capillary C4d expression in renal allograft biopsies","volume":"6","author":"Meehan","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026031808523615900_bib23","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/ctr.12645","article-title":"The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy","volume":"30","author":"Wu","year":"2016","journal-title":"Clin Transplant"},{"key":"2026031808523615900_bib24","first-page":"2580","article-title":"Antibody-mediated rejection of solid-organ allografts","volume":"379","author":"Lefaucheur","year":"2018","journal-title":"N Engl J Med"},{"key":"2026031808523615900_bib25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/his.13855","article-title":"Clinical-pathological correlations in post-transplant thrombotic microangiopathy","volume":"75","author":"Broecker","year":"2019","journal-title":"Histopathology"},{"key":"2026031808523615900_bib26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajt.2025.08.019","article-title":"Evolving landscape of thrombotic microangiopathy in kidney transplant recipients in the post-C5 inhibitor era","author":"Drapeau","year":"2025","journal-title":"Am J Transplant"},{"key":"2026031808523615900_bib27","doi-asserted-by":"publisher","first-page":"S551","DOI":"10.33549\/physiolres.934801","article-title":"Antibody-mediated rejection of renal allografts: diagnostic pitfalls and challenges","volume":"70","author":"Novotn\u00fd","year":"2021","journal-title":"Physiol Res"},{"key":"2026031808523615900_bib28","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1097\/TP.0b013e31827e31c9","article-title":"Acute but transient release of terminal complement complex after reperfusion in clinical kidney transplantation","volume":"95","author":"de Vries","year":"2013","journal-title":"Transplantation"},{"key":"2026031808523615900_bib29","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1681\/ASN.2012111064","article-title":"Cyclosporine induces endothelial cell release of complement-activating microparticles","volume":"24","author":"Renner","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2026031808523615900_bib30","doi-asserted-by":"publisher","first-page":"2724","DOI":"10.1093\/ndt\/gfl340","article-title":"Everolimus inhibits glomerular endothelial cell proliferation and VEGF, but not long-term recovery in experimental thrombotic microangiopathy","volume":"21","author":"Keller","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"2026031808523615900_bib31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.thromres.2013.07.004","article-title":"Treatment with everolimus is associated with a procoagulant state","volume":"132","author":"Baas","year":"2013","journal-title":"Thromb Res"},{"key":"2026031808523615900_bib32","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.transproceed.2014.07.062","article-title":"Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation","volume":"46","author":"Nava","year":"2014","journal-title":"Transplant Proc"},{"key":"2026031808523615900_bib33","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/j.1600-6143.2004.00428.x","article-title":"Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination","volume":"4","author":"Fortin","year":"2004","journal-title":"Am J Transplant"},{"key":"2026031808523615900_bib34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1034\/j.1600-6143.2003.00051.x","article-title":"Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage?","volume":"3","author":"Robson","year":"2003","journal-title":"Am J Transplant"},{"key":"2026031808523615900_bib35","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/00007890-199902270-00009","article-title":"FK506-associated thrombotic microangiopathy: report of two cases and review of the literature","volume":"67","author":"Trimarchi","year":"1999","journal-title":"Transplantation"},{"key":"2026031808523615900_bib36","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/ajh.20887","article-title":"Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah\u2019s Witness","volume":"82","author":"Martin","year":"2007","journal-title":"Am J Hematol"},{"key":"2026031808523615900_bib37","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1097\/TXD.0000000000001239","article-title":"Rejection-associated phenotype of de novo thrombotic microangiopathy represents a risk for premature graft loss","volume":"7","author":"Petr","year":"2021","journal-title":"Transplant Direct"},{"key":"2026031808523615900_bib38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4103\/ijot.ijot_51_19","article-title":"Hyperacute rejection in a blood group incompatible renal transplant recipient enigma of unfathomable thrombotic microangiopathy!","volume":"13","author":"Sood","year":"2019","journal-title":"Indian J Transplant"},{"key":"2026031808523615900_bib39","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ekir.2024.12.031","article-title":"Early thrombotic microangiopathy after ABO-incompatible living donor kidney transplantation","volume":"10","author":"Bertrand","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026031808523615900_bib40","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1590\/2175-8239-jbn-2020-0048","article-title":"Hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli in a renal transplant recipient case report","volume":"43","author":"Nieto-Rios","year":"2021","journal-title":"J Bras Nefrol"},{"key":"2026031808523615900_bib41","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1016\/j.ekir.2025.08.004","article-title":"Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome in adult kidney transplant recipients","volume":"10","author":"Mazloum","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026031808523615900_bib42","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12882-023-03326-8","article-title":"Thrombotic microangiopathies after kidney transplantation in modern era: nosology based on chronology","volume":"24","author":"Von Tokarski","year":"2023","journal-title":"BMC Nephrol"},{"key":"2026031808523615900_bib43","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/ndt\/gfn657","article-title":"Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib","volume":"24","author":"Boll\u00e9e","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2026031808523615900_bib44","doi-asserted-by":"publisher","first-page":"1088031","DOI":"10.3389\/fphar.2022.1088031","article-title":"Drug-induced thrombotic microangiopathy: an updated review of causative drugs, pathophysiology, and management","volume":"13","author":"Mazzierli","year":"2022","journal-title":"Front Pharmacol"},{"key":"2026031808523615900_bib45","doi-asserted-by":"publisher","first-page":"100857","DOI":"10.1016\/j.trre.2024.100857","article-title":"Recurrent complement-mediated hemolytic uremic syndrome after kidney transplantation","volume":"38","author":"Obata","year":"2024","journal-title":"Transplant Rev"},{"key":"2026031808523615900_bib46","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/ajt.12077","article-title":"Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome","volume":"13","author":"Le Quintrec","year":"2013","journal-title":"Am J Transplant"},{"key":"2026031808523615900_bib47","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1681\/ASN.2019040331","article-title":"Use of highly individualized complement blockade has revolutionized clinical outcomes after kidney transplantation and renal epidemiology of atypical hemolytic uremic syndrome","volume":"30","author":"Zuber","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2026031808523615900_bib48","doi-asserted-by":"publisher","first-page":"462","DOI":"10.4103\/ijot.ijot_5_24","article-title":"Early recurrence of C3 glomerulopathy postrenal transplant manifesting as Atypical hemolytic uremic syndrome: a phenotype switch","volume":"18","author":"Siddini","year":"2024","journal-title":"Indian J Transplant"},{"key":"2026031808523615900_bib49","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1182\/blood.2022018833","article-title":"Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study","volume":"142","author":"Brocklebank","year":"2023","journal-title":"Blood"},{"key":"2026031808523615900_bib50","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/ckj\/sfx081","article-title":"Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea","volume":"10","author":"Brocklebank","year":"2017","journal-title":"Clin Kidney J"},{"key":"2026031808523615900_bib51","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.ekir.2018.05.015","article-title":"Cobalamin C deficiency induces a typical histopathological pattern of renal arteriolar and glomerular thrombotic microangiopathy","volume":"3","author":"Lemoine","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2026031808523615900_bib52","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/ng.2590","article-title":"Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome","volume":"45","author":"Lemaire","year":"2013","journal-title":"Nat Genet"},{"key":"2026031808523615900_bib53","doi-asserted-by":"publisher","first-page":"e146959","DOI":"10.1172\/jci.insight.146959","article-title":"Loss of diacylglycerol kinase \u03b5 causes thrombotic microangiopathy by impairing endothelial VEGFA signaling","volume":"6","author":"Liu","year":"2021","journal-title":"JCI Insight"},{"key":"2026031808523615900_bib54","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1681\/ASN.2017010031","article-title":"The phenotypic spectrum of nephropathies associated with mutations in diacylglycerol kinase \u03b5","volume":"28","author":"Azukaitis","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026031808523615900_bib55","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1016\/j.kint.2020.01.045","article-title":"Long-term outcomes and response to treatment in diacylglycerol kinase epsilon nephropathy","volume":"97","author":"Brocklebank","year":"2020","journal-title":"Kidney Int"},{"key":"2026031808523615900_bib56","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"2026031808523615900_bib57","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026031808523615900_bib58","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.kint.2023.07.020","article-title":"On the relevance of thrombomodulin variants in atypical hemolytic uremic syndrome","volume":"104","author":"Huerta","year":"2023","journal-title":"Kidney Int"},{"key":"2026031808523615900_bib59","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","article-title":"Statistical validation of rare complement variants provides insights into the molecular basis of atypical hemolytic uremic syndrome and C3 glomerulopathy","volume":"200","author":"Osborne","year":"2018","journal-title":"J Immunol"},{"key":"2026031808523615900_bib60","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1681\/ASN.2018070759","article-title":"Genetic analysis of 400 patients refines understanding and implicates a new gene in atypical hemolytic uremic syndrome","volume":"29","author":"Bu","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2026031808523615900_bib61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40472-025-00466-8","article-title":"Complement-mediated kidney disease and living donor transplantation: tailoring approaches to improve outcomes","volume":"12","author":"Memon","year":"2025","journal-title":"Curr Transplant Rep"},{"key":"2026031808523615900_bib62","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ajt.2023.02.020","article-title":"Genetic evaluation of living kidney donor candidates: a review and recommendations for best practices","volume":"23","author":"Thomas","year":"2023","journal-title":"Am J Transplant"},{"key":"2026031808523615900_bib63","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1093\/ndt\/gfaf092","article-title":"Chronic kidney disease of unexplained cause (CKDx): a consensus statement by the Genes & Kidney Working Group of the ERA","volume":"40","author":"Halbritter","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026031808523615900_bib64","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1111\/j.1600-6143.2008.02297.x","article-title":"Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation","volume":"8","author":"Le Quintrec","year":"2008","journal-title":"Am J Transplant"},{"key":"2026031808523615900_bib65","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrneph.2010.155","article-title":"New insights into postrenal transplant hemolytic uremic syndrome","volume":"7","author":"Zuber","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2026031808523615900_bib66","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s40620-023-01588-x","article-title":"Propensity score-matched analysis of long-term outcomes for living kidney donation in alternative complement pathway diseases: a pilot study","volume":"36","author":"Caliskan","year":"2023","journal-title":"J Nephrol"},{"key":"2026031808523615900_bib67","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/modpathol.2017.154","article-title":"Genetic testing of complement and coagulation pathways in patients with severe hypertension and renal microangiopathy","volume":"31","author":"Larsen","year":"2018","journal-title":"Mod Pathol"},{"key":"2026031808523615900_bib68","doi-asserted-by":"publisher","first-page":"1112257","DOI":"10.3389\/fimmu.2023.1112257","article-title":"An ex vivo test to investigate genetic factors conferring susceptibility to atypical haemolytic uremic syndrome","volume":"14","author":"Gastoldi","year":"2023","journal-title":"Front Immunol"},{"key":"2026031808523615900_bib69","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.kint.2015.12.003","article-title":"Diagnosis of complement alternative pathway disorders","volume":"89","author":"Angioi","year":"2016","journal-title":"Kidney Int"},{"key":"2026031808523615900_bib70","doi-asserted-by":"publisher","first-page":"113824","DOI":"10.1016\/j.jim.2025.113824","article-title":"Challenges for complement functional assays in the clinical laboratory: from test validation to clinical interpretation","volume":"537","author":"Nandakumar","year":"2025","journal-title":"J Immunol Methods"},{"key":"2026031808523615900_bib71","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1182\/blood.2021012037","article-title":"Functional characterization of 105 factor H variants associated with aHUS: lessons for variant classification","volume":"138","author":"Mart\u00edn Merinero","year":"2021","journal-title":"Blood"},{"key":"2026031808523615900_bib72","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaci.2019.09.009","article-title":"Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: a working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma & Immunology","volume":"145","author":"Chinn","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"2026031808523615900_bib73","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"key":"2026031808523615900_bib74","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJMc0808527","article-title":"Eculizumab for atypical hemolytic-uremic syndrome","volume":"360","author":"N\u00fcrnberger","year":"2009","journal-title":"N Engl J Med"},{"key":"2026031808523615900_bib75","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"2026031808523615900_bib76","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"2026031808523615900_bib77","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"2026031808523615900_bib78","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.ekir.2021.03.884","article-title":"Long-term efficacy and safety of the long-acting complement C5 inhibitor Ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults","volume":"6","author":"Barbour","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026031808523615900_bib79","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1056\/NEJMc1001060","article-title":"Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome","volume":"362","author":"Zimmerhackl","year":"2010","journal-title":"N Engl J Med"},{"key":"2026031808523615900_bib80","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1097\/TP.0000000000004355","article-title":"Assessing the impact of prophylactic eculizumab on renal graft survival in atypical hemolytic uremic syndrome","volume":"107","author":"Glover","year":"2023","journal-title":"Transplantation"},{"key":"2026031808523615900_bib81","doi-asserted-by":"publisher","first-page":"e1289","DOI":"10.1097\/TXD.0000000000001289","article-title":"Ravulizumab in preemptive living donor kidney transplantation in hereditary atypical hemolytic uremic syndrome","volume":"8","author":"Schmidt","year":"2022","journal-title":"Transplant Direct"},{"key":"2026031808523615900_bib82","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1080\/17843286.2017.1345185","article-title":"Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome","volume":"73","author":"Claes","year":"2018","journal-title":"Acta Clin Belg"},{"key":"2026031808523615900_bib83","doi-asserted-by":"publisher","first-page":"101392","DOI":"10.1016\/j.lanepe.2025.101392","article-title":"Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial","author":"Bryant","year":"2025","journal-title":"Lancet Regional Health\u2014Europe"},{"key":"2026031808523615900_bib84","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/ndt\/gfaf166","article-title":"Cost-effectiveness of lifelong eculizumab versus disease monitoring of aHUS","volume":"41","author":"Orozco-Leal","year":"2026","journal-title":"Nephrol Dial Transplant"},{"key":"2026031808523615900_bib85","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1053\/j.ajkd.2017.06.024","article-title":"Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series","volume":"70","author":"Duineveld","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2026031808523615900_bib86","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ekir.2023.01.016","article-title":"Eculizumab rescue therapy in patients with recurrent atypical hemolytic uremic syndrome after kidney transplantation","volume":"8","author":"Duineveld","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026031808523615900_bib87","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1097\/TP.0000000000005135","article-title":"Kidney transplantation in patients with aHUS: a comparison of eculizumab prophylaxis versus rescue therapy","volume":"109","author":"Duineveld","year":"2025","journal-title":"Transplantation"},{"key":"2026031808523615900_bib88","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1681\/ASN.2008080906","article-title":"Liver-kidney transplantation to cure atypical hemolytic uremic syndrome","volume":"20","author":"Saland","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2026031808523615900_bib89","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","article-title":"Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies","volume":"8","author":"Zuber","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"2026031808523615900_bib90","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1097\/TP.0b013e3181a991ca","article-title":"Belatacept as immunosuppression in patient with recurrence of hemolytic uremic syndrome after renal transplantation","volume":"87","author":"Midtvedt","year":"2009","journal-title":"Transplantation"},{"key":"2026031808523615900_bib91","doi-asserted-by":"publisher","first-page":"e1825","DOI":"10.1097\/TXD.0000000000001825","article-title":"Thrombotic microangiopathy after kidney pancreas transplant managed with eculizumab and a calcineurin inhibitor-free basiliximab\/belatacept maintenance regimen: between a rock and a hard place","volume":"11","author":"Chen","year":"2025","journal-title":"Transplant Direct"},{"key":"2026031808523615900_bib92","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.ekir.2024.01.013","article-title":"\u201cEculizumab first\u201d in the management of posttransplant thrombotic microangiopathy","volume":"9","author":"Maritati","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026031808523615900_bib93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.4285\/kjt.22.0050","article-title":"The first successful eculizumab rescue therapy of a kidney transplant recipient with atypical hemolytic uremic syndrome in South Korea: a case report","volume":"37","author":"Min","year":"2023","journal-title":"Korean J Transplant"},{"key":"2026031808523615900_bib94","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s40620-022-01391-0","article-title":"De novo systemic atypical hemolytic uremic syndrome in an ABO-incompatible living kidney transplant recipient with a novel pathogenic CFHR1 gene mutation successfully treated with eculizumab: a case report","volume":"35","author":"Li","year":"2022","journal-title":"J Nephrol"},{"key":"2026031808523615900_bib95","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1055\/a-1380-1668","article-title":"De novo thombotic microangiopathy (TMA) after incompatible AB0 renal transplantation","volume":"146","author":"Kolb","year":"2021","journal-title":"Dtsch Med Wochenschr"},{"key":"2026031808523615900_bib96","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/ckj\/sfaa096","article-title":"Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study","volume":"14","author":"Portoles","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026031808523615900_bib97","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.xkme.2020.06.007","article-title":"Use of eculizumab in transplant-associated thrombotic microangiopathy in a patient with polycystic kidney disease immediately post-kidney transplant: a case report","volume":"2","author":"Godara","year":"2020","journal-title":"Kidney Med"},{"key":"2026031808523615900_bib98","doi-asserted-by":"publisher","first-page":"e13885","DOI":"10.1111\/ctr.13885","article-title":"De novo thrombotic microangiopathy in two kidney transplant recipients from the same deceased donor: a case series","volume":"34","author":"Roberts","year":"2020","journal-title":"Clin Transplant"},{"key":"2026031808523615900_bib99","first-page":"1727986","article-title":"De novo atypical haemolytic uremic syndrome after kidney transplantation","volume":"2018","author":"Devresse","year":"2018","journal-title":"Case Rep Nephrol"},{"key":"2026031808523615900_bib100","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in secondary atypical haemolytic uraemic syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2026031808523615900_bib101","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1159\/000468528","article-title":"Hemolytic uremic syndrome and kidney transplantation: a case series and review of the literature","volume":"136","author":"Milan Manani","year":"2017","journal-title":"Nephron"},{"key":"2026031808523615900_bib102","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/nep.12936","article-title":"De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab","volume":"22","author":"Shochet","year":"2017","journal-title":"Nephrology"},{"key":"2026031808523615900_bib103","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.transproceed.2016.11.008","article-title":"Eculizumab and belatacept for de novo atypical hemolytic uremic syndrome associated with CFHR3-CFHR1 deletion in a kidney transplant recipient: a case report","volume":"49","author":"Dedhia","year":"2017","journal-title":"Transplant Proc"},{"key":"2026031808523615900_bib104","doi-asserted-by":"publisher","first-page":"3106","DOI":"10.1016\/j.transproceed.2016.04.005","article-title":"Belatacept and eculizumab for treatment of calcineurin inhibitor-induced thrombotic microangiopathy after kidney transplantation: case report","volume":"48","author":"Merola","year":"2016","journal-title":"Transplant Proc"},{"key":"2026031808523615900_bib105","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.nefro.2016.02.003","article-title":"Late onset of de novo atypical hemolytic-uremic syndrome presented on a simultaneous pancreas and kidney transplant recipient successfully treated with eculizumab","volume":"36","author":"Juega-Mari\u00f1o","year":"2016","journal-title":"Nefrologia"},{"key":"2026031808523615900_bib106","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/tri.12582","article-title":"Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature","volume":"28","author":"Java","year":"2015","journal-title":"Transpl Int"},{"key":"2026031808523615900_bib107","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5414\/CN108163","article-title":"Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: a case report","volume":"83","author":"Safa","year":"2015","journal-title":"Clin Nephrol"},{"key":"2026031808523615900_bib108","doi-asserted-by":"publisher","first-page":"bcr2014207630","DOI":"10.1136\/bcr-2014-207630","article-title":"A \u2018silent\u2019, new polymorphism of factor H and apparent de novo atypical haemolytic uraemic syndrome after kidney transplantation","volume":"2014","author":"Broeders","year":"2014","journal-title":"BMJ Case Rep"},{"key":"2026031808523615900_bib109","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/j.transproceed.2011.02.064","article-title":"Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation\u2014a case report","volume":"43","author":"Chandran","year":"2011","journal-title":"Transplant Proc"},{"key":"2026031808523615900_bib110","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1097\/TP.0b013e318230c0bd","article-title":"Successful treatment of de novo posttransplant thrombotic microangiopathy with eculizumab","volume":"92","author":"Wilson","year":"2011","journal-title":"Transplantation"},{"key":"2026031808523615900_bib111","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1600-6143.2008.02482.x","article-title":"Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy","volume":"9","author":"Ashman","year":"2009","journal-title":"Am J Transplant"},{"key":"2026031808523615900_bib112","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1111\/ajt.16430","article-title":"Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept","volume":"21","author":"Chavarot","year":"2021","journal-title":"Am J Transplant"},{"key":"2026031808523615900_bib113","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1182\/blood.2019003399","article-title":"The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria","volume":"135","author":"R\u00f6th","year":"2020","journal-title":"Blood"},{"key":"2026031808523615900_bib114","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/S0140-6736(25)01148-1","article-title":"Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study","volume":"406","author":"Kavanagh","year":"2025","journal-title":"Lancet"},{"key":"2026031808523615900_bib115","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1056\/NEJMoa2501510","article-title":"Trial of pegcetacoplan in C3 glomerulopathy and immune-complex MPGN","volume":"393","author":"Fakhouri","year":"2025","journal-title":"N Engl J Med"},{"key":"2026031808523615900_bib116","doi-asserted-by":"publisher","first-page":"12168","DOI":"10.3389\/ti.2024.12168","article-title":"Unveiling the incidence and graft survival rate in kidney transplant recipients with de novo thrombotic microangiopathy: a systematic review and meta-analysis","volume":"37","author":"Hsiung","year":"2024","journal-title":"Transpl Int"},{"key":"2026031808523615900_bib117","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/tri.13022","article-title":"Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis","volume":"30","author":"Legendre","year":"2017","journal-title":"Transpl Int"},{"key":"2026031808523615900_bib118","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","article-title":"Eculizumab use for kidney transplantation in patients with a diagnosis of Atypical hemolytic uremic syndrome","volume":"4","author":"Siedlecki","year":"2019","journal-title":"Kidney Int Rep"},{"key":"2026031808523615900_bib119","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3390\/jcm8070919","article-title":"Outcomes of kidney transplant patients with atypical hemolytic uremic syndrome treated with eculizumab: a systematic review and meta-analysis","volume":"8","author":"Gonzalez Suarez","year":"2019","journal-title":"J Clin Med"},{"key":"2026031808523615900_bib120","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1073\/pnas.0603420103","article-title":"Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome","volume":"104","author":"Goicoechea de Jorge","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026031808523615900_bib121","doi-asserted-by":"publisher","first-page":"3058","DOI":"10.1111\/trf.14326","article-title":"Successful kidney transplantation in a patient with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome)","volume":"57","author":"Fattah","year":"2017","journal-title":"Transfusion"},{"key":"2026031808523615900_bib122","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/cge.14105","article-title":"A splice site mutation in the TSEN2 causes a new syndrome with craniofacial and central nervous system malformations, and atypical hemolytic uremic syndrome","volume":"101","author":"Canpolat","year":"2022","journal-title":"Clin Genet"},{"key":"2026031808523615900_bib123","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.ekir.2023.07.024","article-title":"Kidney-predominant thrombotic microangiopathy associated with TREX1 frameshift mutation","volume":"8","author":"Song","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026031808523615900_bib124","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag018\/66564639\/sfag018.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/3\/sfag018\/66564639\/sfag018.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/3\/sfag018\/66564639\/sfag018.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:56:49Z","timestamp":1773838609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag018\/8440143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":124,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag018","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,1,24]]},"article-number":"sfag018"}}